Canaloplasty is a minimally invasive glaucoma surgical procedure designed to improve conventional outflow using 360° microcatheterization and pressurized viscodilation. The goal is to enhance flow through the trabecular meshwork, Schlemm’s canal and collector channels while working with the eye’s natural drainage anatomy. Microcatheter-based systems such as iTrack™ Advance support this approach with illuminated navigation and pressurized viscoelastic delivery.
1. Glaucoma Specialists & iTrack. "Discover iTRACK™ for Glaucoma." https://glaucoma-itrack.com/us/.
2. Glaucoma Associates of Texas. "Gonioscopy-Assisted Transluminal Trabeculotomy (GATT)." https://www.glaucomaassociates.com/gonioscopy-assisted-transluminal-trabeculotomy/.
3. Lewis, R.A., et al. "Canaloplasty: Three-Year Results." Journal of Cataract & Refractive Surgery, vol. 37, no. 4, 2011, pp. 682-690. PMID: 21420593. https://pubmed.ncbi.nlm.nih.gov/21420593/
Targets multiple resistance sites: Canaloplasty addresses all three sites: trabecular meshwork, Schlemm's canal, and collector channels. Most other MIGS address only 1-2 sites; stents primarily address trabecular meshwork, while TM-cutting procedures address only trabecular meshwork.
1.Banerjee, A., et al. "Comparison of Superior versus Inferior Canaloplasty and Goniotomy with OMNI Surgical System." PLoS ONE, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11214751/
2. Patel, K., & Reiss, G. "Long-Term Clinical and Safety Outcomes of Canaloplasty Performed with iTrack Microcatheter." PLoS ONE, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10191748/
3. Meta-analysis authors. "Safety and Efficacy of Canaloplasty versus Trabeculectomy in Open-Angle Glaucoma." Oncotarget, 2019. https://www.oncotarget.com/article/14757/text/
Physiological restoration of natural aqueous outflow: Canaloplasty rejuvenates and re-establishes the eye’s natural drainage system across the entire conventional outflow pathway without creating artificial bypasses, shunts, or tissue removal.
1. Arosemena A, Simpson RG, Bedrood S, Camejo L, Funke CM, Kamat S, Qiu M. Canaloplasty: how it works and where it fits in the MIGS armamentarium. Glaucoma Today. 2025 Mar/Apr suppl. https://glaucomatoday.com/articles/2025-mar-apr-supplement/canaloplasty-how-it-works-and-where-it-fits-in-the-migs-armamentarium
Nova Eye Medical, equips your surgeons with the best equipment for a non-destructive, long-term, patient care focused solution.
The iTrack™ Advance has a CE Mark (Conformité Européenne) 2862 and US Food and Drug Administration (FDA) 510(k) #K221872 for the treatment of open-angle glaucoma.
INDICATIONS (USA): The iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures.* The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma.The ab interno surgical technique is not a cleared indication of the iTrack™ Advance in the USA.
*The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.
CONTRAINDICATIONS (USA): The iTrack™ Advance is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: Neovascular glaucoma; Angle-closure glaucoma; Previous surgery with resultant scarring of Schlemm’s canal.
PRECAUTIONS (USA): The iTrack™ Advance should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.
© 2026. Nova Eye, Inc. E&OE. Patents pending and/or granted. iTrack™ Advance, iTrack™, ViscoInjector™ and iLumin™ are trademarks of Nova Eye, Inc.
The iTrack™ has a CE Mark (Conformité Européenne) 2862 and US Food and Drug Administration (FDA) 510(k) #K080067 for the treatment of open-angle glaucoma.
INDICATIONS: The iTrack™ canaloplasty microcatheter is indicated for fluid infusion or aspiration during surgery. The iTrack™ canaloplasty microcatheter is indicated for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in adult patients with open-angle glaucoma.The ab interno surgical technique is not a cleared indication for the iTrack™ in the USA.
CONTRAINDICATIONS: The iTrack™ canaloplasty microcatheter is not intended to be used for catheterization and viscodilation of Schlemm’s canal to reduce intraocular pressure in eyes of patients with the following conditions: neovascular glaucoma; angle closure glaucoma; and, previous surgery with resultant scarring of Schlemm’s canal.
ADVERSE EVENTS: Possible adverse events with the use of the iTrack™ canaloplasty microcatheter include, but are not limited to: hyphema, elevated IOP, Descemet’s membrane detachment, shallow or flat anterior chamber, hypotony, trabecular meshwork rupture, choroidal effusion, Peripheral Anterior Synechiae (PAS) and iris prolapse.
WARNINGS: The iTrack™ canaloplasty microcatheter is intended for one time use only. DO NOT re-sterilize and/or reuse, as this can compromise device performance and increase the risk of cross contamination due to inappropriate reprocessing.
PRECAUTIONS: The iTrack™ canaloplasty microcatheter should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.
